Navigation Links
Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
Date:7/31/2008

ade pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigati
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
4. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
5. Genta Announces Second Quarter 2008 Financial Results and Conference Call
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant
8. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
9. Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
10. Bioheart, Inc. Announces Results of Annual Meeting
11. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) ... in the HIV-1 therapeutic space, announced today a ... Institute (NCI) to further the development of the ... inhibitors are a novel class of antiretroviral drug ...
... of California, Riverside engineering professor and a team of ... material that could play a major role in keeping ... Balandin, a professor of electrical engineering at the UC ... University of Texas at Austin, The University of Texas ...
... by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the ... combination of Equity, and Debt Conversion. ... Biologics. After completing the acquisition of the Global ... early last year, Pinnacle continues the process of ...
Cached Biology Technology:DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs 3Keeping electronics cool 2Keeping electronics cool 3Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round 2Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round 3
(Date:7/25/2014)... the first time, Spanish researchers have detected an unknown ... cells are introduced into a droplet of salt ... sodium chloride crystallisation to create biomineralogical biosaline 3D morphologically ... the material, bacteria are revived. The discovery was made ... the cover of the Astrobiology journal and ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... on average over a 35 year period in which ... impact of humans on declining animal numbers. This decline ... insects, spiders, crustaceans, slugs and worms bring to our ... decomposition for nutrient cycling, water filtration and human health. ... led by UCL, Stanford and UCSB, focused on the ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... CAAugust 14, 2011Scientists at the Gladstone Institutes have gained new ... out of balance, can prevent the normal development of stem ... some types of cancer. "The news, being announced in ... , adds to the understanding of the role of stem ...
... Extinction is a focal issue among scientists, policy makers ... are thought to have disappeared are rediscovered. Yet, these ... from the National University of Singapore (NUS), University of ... 122 years, at least 351 species which are thought ...
... the direct impact of fishing as the largest known ... sea lion population. The team,s findings, published in ... and identifies resource competition and by-catch incidents as the ... Phocarctos hookeri is the country,s only native pinniped species ...
Cached Biology News:Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3Rediscovery of disappeared species: Truly back from the brink? 2Competition with humans responsible for decline of New Zealand's endangered sea lions, study shows 2
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... crosslinked to protein G-agarose beads which can ... heart mitochondria. Also included are 2 mg ... ,The pyruvate dehydrogenase complex (PDH) immunocapture kit ... of tissue. This facilitates the subsequent analysis ...
... PULSin may be superior to transfection in ... transfection, with PULSin you can study lethal ... course of proteins in cells. Likewise, delivery ... than traditional RNA interference experiments. ,With ...
Biology Products: